

# Spyridon K Karadimas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/188666/publications.pdf>

Version: 2024-02-01

18  
papers

1,895  
citations

567281

15  
h-index

888059

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Degenerative Cervical Myelopathy. <i>Spine</i> , 2015, 40, E675-E693.	2.0	630
2	Cervical Spondylotic Myelopathy. <i>Neuroscientist</i> , 2013, 19, 409-421.	3.5	318
3	Pathophysiology and Natural History of Cervical Spondylotic Myelopathy. <i>Spine</i> , 2013, 38, S21-S36.	2.0	303
4	A novel experimental model of cervical spondylotic myelopathy (CSM) to facilitate translational research. <i>Neurobiology of Disease</i> , 2013, 54, 43-58.	4.4	117
5	Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. <i>Science Translational Medicine</i> , 2015, 7, 316ra194.	12.4	84
6	Synergistic effects of self-assembling peptide and neural stem/progenitor cells to promote tissue repair and forelimb functional recovery in cervical spinal cord injury. <i>Biomaterials</i> , 2014, 35, 2617-2629.	11.4	83
7	Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. <i>Neurobiology of Disease</i> , 2014, 62, 394-406.	4.4	64
8	Cervical excitatory neurons sustain breathing after spinal cord injury. <i>Nature</i> , 2018, 562, 419-422.	27.8	56
9	Sensory cortical control of movement. <i>Nature Neuroscience</i> , 2020, 23, 75-84.	14.8	45
10	Clinical Evaluation of a Neuroprotective Drug in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. <i>Spine</i> , 2013, 38, S68-S75.	2.0	38
11	Immunohistochemical Profile of NF- $\kappa$ B/p50, NF- $\kappa$ B/p65, MMP-9, MMP-2, and u-PA in Experimental Cervical Spondylotic Myelopathy. <i>Spine</i> , 2013, 38, 4-10.	2.0	38
12	Bilateral Contusion-Compression Model of Incomplete Traumatic Cervical Spinal Cord Injury. <i>Journal of Neurotrauma</i> , 2014, 31, 1776-1788.	3.4	38
13	Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury. <i>PLoS ONE</i> , 2014, 9, e96137.	2.5	27
14	<i>Mir21</i> modulates inflammation and sensorimotor deficits in cervical myelopathy: data from humans and animal models. <i>Brain Communications</i> , 2021, 3, fcaa234.	3.3	27
15	The Impact of Riluzole on Neurobehavioral Outcomes in Preclinical Models of Traumatic and Nontraumatic Spinal Cord Injury: Results From a Systematic Review of the Literature. <i>Global Spine Journal</i> , 2020, 10, 216-229.	2.3	19
16	The Sodium Channel/Glutamate Blocker Riluzole is Complementary to Decompression in a Preclinical Experimental Model of Cervical Spondylotic Myelopathy (CSM). <i>Neurosurgery</i> , 2012, 71, E543.	1.1	7
17	Riluzole Attenuates the Decompression-Induced Ischemia Reperfusion Injury and Enhances the Beneficial Impact of Decompression in Cervical Spondylotic Myelopathy. <i>Spine Journal</i> , 2015, 15, S158-S159.	1.3	1
18	Combinatorial Surgical and Neuroprotective Therapy for Cervical Spondylotic Myelopathy Results in Improved Neurological Function: From Preclinical Proof of Concept to a Phase III Randomized Controlled Trial. <i>Spine Journal</i> , 2017, 17, S138.	1.3	0